Skip to main content
. Author manuscript; available in PMC: 2023 Oct 19.
Published in final edited form as: Glia. 2021 Aug 30;69(12):2981–2998. doi: 10.1002/glia.24083

FIGURE 12: Remyelination and astrogliosis in the Glast1-FthKO brain.

FIGURE 12:

(A) PLP and GFAP immunostaining in untreated, control and Glast1-FthKO mice at the end of the CPZ treatment (7W CPZ) and after 2 and 4 weeks of recovery (2W and 4W Rec). Scale bar=180μm. (B and C) PLP and MBP fluorescent intensity and total numbers of Olig2 and CC1-positive cells in the CX of untreated, control and Glast1-FthKO mice at the end of the CPZ treatment (7W CPZ) and after 2 and 4 weeks of recovery (2W and 4W Rec). (D) Percentage of Olig2/CC1 double-positive cells in the CX. (E) GFAP fluorescent intensity and total numbers of GFAP and GFAP/Ki67-positive cells in the CX under the same experimental conditions. Fluorescent intensity data is presented as percent of untreated mice. Values are expressed as mean ± SEM. ### p<0.001 versus untreated; *p<0.05, **p<0.01, ***p<0.001 vs. respective controls.